EQS-News: Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
|
EQS-News: Biotest AG
/ Key word(s): AGM/EGM
PRESS RELEASE Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
Dreieich, 23 October 2025. Biotest AG hereby announces that its majority shareholder, Grifols S.A., Barcelona, Spain, informed the Management Board on 22 October 2025 that it is withdrawing from the request as of 1 August 2025 to convene an extraordinary general meeting. In the same letter, Grifols S.A. also requested the convening of an extraordinary general meeting to resolve on the change of legal form of Biotest AG from a stock corporation (Aktiengesellschaft, AG) into a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA). The Supervisory Board was immediately informed of the receipt of this request. The Management Board with the approval of the Supervisory Board decided to cancel the extraordinary general meeting scheduled for 28 October 2025. The Management Board will carefully review the new request of Grifols S.A. to convene an extraordinary general meeting to resolve on the change of legal form of the company into a partnership limited by shares (KGaA), pursuant to Section 122 (1) of the German Stock Corporation Act (AktG). If the new request for convocation is admissible, the Management Board will invite again to an extraordinary general meeting. The details will be published by the company.
About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406
PR contact Miriam Oehme Phone: +49 -152 07016 992
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Disclaimer
23.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2217676 23.10.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 419,10 | 484,20 | 515,60 | 516,10 | 684,60 | 726,20 | 680,00 | |
| EBITDA1,2 | 30,50 | 28,30 | -16,10 | 19,20 | 179,40 | 135,10 | -24,00 | |
| EBITDA-Margin3 | 7,28 | 5,85 | -3,12 | 3,72 | 26,21 | 18,60 | -3,53 | |
| EBIT1,4 | -1,20 | -1,30 | -47,10 | -16,60 | 143,50 | 94,50 | -67,00 | |
| EBIT-Margin5 | -0,29 | -0,27 | -9,14 | -3,22 | 20,96 | 13,01 | -9,85 | |
| Net Profit (Loss)1 | -4,70 | -31,40 | -63,40 | -31,70 | 127,00 | 26,40 | -110,00 | |
| Net-Margin6 | -1,12 | -6,49 | -12,30 | -6,14 | 18,55 | 3,64 | -16,18 | |
| Cashflow1,7 | -33,60 | -16,70 | 33,90 | -40,50 | -2,70 | 60,90 | -125,00 | |
| Earnings per share8 | -0,11 | -0,72 | 1,59 | -0,79 | 3,22 | 0,68 | -2,75 | |
| Dividend per share8 | 0,04 | 0,04 | 0,04 | 0,00 | 0,08 | 0,04 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Biotest VZ | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| 522723 | DE0005227235 | AG | 1.341,47 Mio € | 14.10.1987 | 9F2C2M4X+6R | |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -23,85 | 19,69 | -1,21 | 206,67 | 2,31 | 20,14 | 1,85 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,08 | 0,04 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 02.07.2025 | 12.05.2025 | 04.08.2025 | 10.11.2025 | 28.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +3,46% | +4,33% | +16,54% | +19,23% | +200,10% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
